5. The subject has at Baseline a total of at least 5 previously untreated SEBs (greatest diameter 5 mm or greater on the face excluding the nose and periorbital skin, 9 mm or greater on non-facial areas excluding the skin below the knees), as documented clinically by the Investigator at Baseline. Untreated is define as no previous surgical or topical or intralesional drug treatment. Previous treatment with systemically administered drugs more than 6 months prior to Baseline is not considered previous treatment as long as there was no clinical evidence of resistance to oral HH (e.g., vismodegib, patidegib, and sonidegib) inhibitors. Baseline treatment targeted SEBs must not exceed a diameter of > 2cm. At least one of these tumors must be appropriate for a 2 mm punch biopsy for biomarker analysis at Baseline and Week 6 visits. If a subject has 5 or more facial, excluding periorbital and nasal skin, SEBs at Baseline, non-facial SEBs will not be treatment targeted SEBs.